Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy

BJU International

Volumn 111, Issue 6, 2013, Pages 954-962

  Chao, Chun ^a   Jacobsen, Steven J ^a   Xu, Lanfang ^a   Wallner, Lauren P ^a   Porter, Kimberly R ^a   Williams, Stephen G ^b  

^a Kaiser Permanente Southern California ^*  (United States)

^b Riverside Medical Center   (United States)

Author keywords

HMG CoA reductase inhibitors; prostate cancer; radical prostatectomy; recurrence; statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; COMORBIDITY; DEMOGRAPHY; DISEASE COURSE; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

CALIFORNIA; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876902126     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11639.x     Document Type: Article

References (30)

1. National Cancer Institute at the National Institutes of Health. Prostate Cancer. Available at: http://www.cancer.gov/cancertopics/types/prostate. Accessed September 2011
2. O'Shaughnessy M, Konety B, Warlick C,. Prostate cancer screening: issues and controversies. Minn Med 2010; 93: 39-44
3. SEER Stat Fact Sheets: Prostate. National Cancer Institute Surveillance, Epidemiology and End Results. 2012
4. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-105
5. Mann D, Reynolds K, Smith D, Muntner P,. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008; 42: 1208-1215
6. Jain MK, Ridker PM,. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987
7. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996; 271: 17453-17462
8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ,. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-519
9. Dulak J, Jozkowicz A,. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 2005; 5: 579-594
10. Koul HK, Kumar B, Koul S, et al. The role of inflammation and infection in prostate cancer: importance in prevention, diagnosis and treatment. Drugs Today (Barc) 2010; 46: 929-943
11. Jackson SM, Ericsson J, Edwards PA,. Signaling molecules derived from the cholesterol biosynthetic pathway. Subcell Biochem 1997; 28: 1-21
12. Benitah SA, Espina C, Valerõn PF, Lacal JC,. Rho GTPases in human carcinogenesis: a tale of excess. Clin Trans Oncol 2003; 5: 70-78
13. Dillard PR, Lin MF, Khan SA,. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 2008; 295: 115-120
14. Forrester JS, Libby P,. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007; 99: 732-738
15. Rosenson RS,. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001; 1: 411-420
16. Yasui Y, Suzuki R, Miyamoto S, et al. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007; 121: 2331-2339
17. Hamilton RJ, Freedland SJ,. Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep 2008; 9: 189-196
18. Boudreau DM, Yu O, Johnson J,. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010; 9: 603-621
19. Bonovas S, Filioussi K, Sitaras NM,. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904
20. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-914
21. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH,. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011; 14: 63-68
22. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK,. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010; 183: 118-124
23. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA,. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011; 185: 1268-1273
24. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389-3398
25. Soto DE, Daignault S, Sandler HM, Ray ME,. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009; 73: 158-162
26. Ritch CR, Hruby G, Badani KK, Benson MC, McKiernan JM,. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108: E211-216
27. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL,. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653-2659
28. Kollmeier MA, Katz MS, Mak K, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 713-718
29. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26: 298-303
30. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE,. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634